

<b>Title: Abecma (idecabtagene vicleucel)</b>	<b>Division: Medical Management</b> <b>Department: Utilization Management</b>
<b>Approval Date: 4/26/2022</b>	<b>LOB: Medicaid, HIV SNP, HARP, CHP, MetroPlus Gold, GoldCare, Marketplace, Essential, Medicare, Ultracare</b>
<b>Effective Date: 4/26/2022</b>	<b>Policy Number: UM-MP334</b>
<b>Review Date: 3/17/2026</b>	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 1 of 5</b>

**I. POLICY DESCRIPTION:**

Medical Oncology – CAR-T immunotherapy, Abecma (idecabtagene vicleucel)

**II. RESPONSIBLE PARTIES:**

Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim Department, Providers Contracting.

**III. DEFINITIONS:**

Abecma is a chimeric antigen receptor (CAR)-positive T-cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of ABECMA results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.

Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

All other uses for Abecma are considered experimental and investigational.

**IV. POLICY:**

**For Medicare and Ultracare Only:** Per CMS regulation, Metroplus Health Plan follows the following National Coverage Determination (NCD) for Chimeric Antigen Receptor (CAR) T-cell Therapy

1. NCD 110.24

**For Medicaid, SNP, HARP Plan members Only:** Confirmed diagnosis of FDA-approved or compendia supported indication and Medicaid covered indication.

**For all other LOBs:**

Abecma will be considered medically necessary once the following coverage criteria is met. Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

**INITIAL REQUEST:**

**1. Adult relapsed or refractory Multiple Myeloma**

- A. Member is 18 years of age or older;

<b>Title: Abecma (idecabtagene vicleucel)</b>	<b>Division: Medical Management Department: Utilization Management</b>
<b>Approval Date: 4/26/2022</b>	<b>LOB: Medicaid, HIV SNP, HARP, CHP, MetroPlus Gold, GoldCare, Marketplace, Essential, Medicare, Ultracare</b>
<b>Effective Date: 4/26/2022</b>	<b>Policy Number: UM-MP334</b>
<b>Review Date: 3/17/2026</b>	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 2 of 5</b>

**AND**

**B.** Member has a diagnosis confirmed by submitted documentation including clinical chart notes of relapsed or refractory Multiple Myeloma;

**AND**

**C.** Member has received prior treatment with at least FOUR prior lines of therapy, including at least ONE drug from ALL of the following categories:

- a.** Immunomodulatory agent (e.g., Thalomid (thalidomide capsules), Revlimid (lenalidomide capsules), Pomalyst (pomalidomide capsules));

**AND**

- b.** Proteasome inhibitor (e.g., Velcade (bortezomib injection), Kyprolis (carfilzomib injection), Ninlaro (ixazomib capsules));

**AND**

- c.** Anti-CD38 monoclonal antibody (e.g., Darzalex (daratumumab intravenous infusion), Darzalex Faspro (daratumumab and hyaluronidase-fihj subcutaneous injection), Sarclisa (isatuximab-irfc intravenous infusion));

**AND**

**D.** Member has measurable disease shown by at least ONE of the following:

- a.** Serum monoclonal paraprotein (M-protein)  $\geq$  1 g/dL;

**OR**

- b.** Urine M-protein  $\geq$  200 mg/24 hours;

**OR**

- c.** Serum immunoglobulin free light chain  $\geq$  10 mg/dL and abnormal serum free light chain ratio;

**AND**

**E.** Member has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;

**AND**

**F.** Member is screened for HBV, HCV, and HIV in accordance with clinical guidelines prior to collection of cells for manufacturing;

**AND**

**G.** Member has not received any live vaccines within the past 6 weeks;

**AND**

**H.** Member does not have an active systemic infection or inflammatory disorder;

**AND**

**I.** Member has not previously been treated with Abecma or any other CAR-T therapy;

**AND**

<b>Title: Abecma (idecabtagene vicleucel)</b>	<b>Division: Medical Management</b> <b>Department: Utilization Management</b>
<b>Approval Date: 4/26/2022</b>	<b>LOB: Medicaid, HIV SNP, HARP, CHP, MetroPlus Gold, GoldCare, Marketplace, Essential, Medicare, Ultracare</b>
<b>Effective Date: 4/26/2022</b>	<b>Policy Number: UM-MP334</b>
<b>Review Date: 3/17/2026</b>	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 3 of 5</b>

J. Authorization is for no more than one dose

**RENEWAL REQUEST:**

Repeat administration of Abecma is investigational and will not be covered.

**V. LIMITATIONS/ EXCLUSIONS:**

- Repeat administration of Abecma is considered to be experimental or investigational because there have been no established studies to demonstrate effectiveness
- History of central nervous system (CNS) disease (such as (such as seizure or cerebrovascular ischemia)
- Requiring ongoing treatment with chronic immunosuppression

**VI. APPLICABLE PROCEDURE CODES:**

CPT	Description
Q2055	Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

**VII. APPLICABLE DIAGNOSIS CODES:**

CODE	Description
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma in relapse
Z51.12	Encounter for antineoplastic immunotherapy

**VIII. REFERENCES:**

1. Abecma [package insert]. Summit, NJ: Celgene Corporation; January 2024.
2. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 348(8): 705-716.
3. The NCCN Clinical Practice Guidelines in Oncology® Multiple Myeloma (Version 3.2024; March 8, 2024). © 2021 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>.
4. NCD - Chimeric Antigen Receptor (CAR) T-cell Therapy (110.24). [www.cms.gov](http://www.cms.gov). Available at: [NCD - Chimeric Antigen Receptor \(CAR\) T-cell Therapy \(110.24\) \(cms.gov\)](https://www.cms.gov/medicare-coverage-database/details/nondurablecoverage.aspx?NCD=110.24)



## Policy and Procedure

<b>Title:</b> Abecma (idecabtagene vicleucel)	<b>Division:</b> Medical Management <b>Department:</b> Utilization Management
<b>Approval Date:</b> 4/26/2022	<b>LOB:</b> Medicaid, HIV SNP, HARP, CHP, MetroPlus Gold, GoldCare, Marketplace, Essential, Medicare, Ultracare
<b>Effective Date:</b> 4/26/2022	<b>Policy Number:</b> UM-MP334
<b>Review Date:</b> 3/17/2026	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 4 of 5</b>

### REVISION LOG:

<b>REVISIONS</b>	<b>DATE</b>
Creation date	4/14/2022
Annual review	4/25/2023
Annual review	4/23/2024
Annual review	5/27/2025
Annual review and update	3/17/2026

**Approved:**

**Date:**

**Approved:**

**Date:**

---

David Ackman, MD  
VP of Medical Director

---

Sanjiv Shah, MD  
Chief Medical Officer



## Policy and Procedure

<b>Title: Abecma (idecabtagene vicleucel)</b>	<b>Division: Medical Management</b> <b>Department: Utilization Management</b>
<b>Approval Date: 4/26/2022</b>	<b>LOB: Medicaid, HIV SNP, HARP, CHP, MetroPlus Gold, GoldCare, Marketplace, Essential, Medicare, Ultracare</b>
<b>Effective Date: 4/26/2022</b>	<b>Policy Number: UM-MP334</b>
<b>Review Date: 3/17/2026</b>	<b>Cross Reference Number:</b>
<b>Retired Date:</b>	<b>Page 5 of 5</b>

### Medical Guideline Disclaimer:

Property of Metro Plus Health Plan. All rights reserved. The treating physician or primary care provider must submit MetroPlus Health Plan clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, Metroplus Health Plan will not be able to properly review the request for prior authorization. The clinical review criteria expressed in this policy reflects how MetroPlus Health Plan determines whether certain services or supplies are medically necessary. MetroPlus Health Plan established the clinical review criteria based upon a review of currently available clinical information(including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between this guidelines and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication. MetroPlus Health Plan has adopted the herein policy in providing management, administrative and other services to our members, related to health benefit plans offered by our organization.